Comments
Dr Reddy’s Laboratories has launched Treprostinil Injection in the U.S. market.
The launched product is a therapeutic equivalent generic version of Remodulin (treprostinil) Injection, approved by the U. S. Food and Drug Administration (USFDA), the Hyderabad-based company said in a release.
Treprostinil injection is a prostacyclin mimetic indicated for patients who require a transition from epoprostenol, to reduce the rate of clinical deterioration.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.